Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis

Overview of attention for article published in Frontiers in oncology, January 2023

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 12 Dimensions

Readers on

mendeley: 7 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 24,623 followers.

Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis https://t.co/KaHoEBV7L5 https://t.co/mFyaeVQScK

27 Jan 2023

Reply Repost Favourite

New research: Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis: Objective This review aimed to comprehensively analyze the safety and… https://t.co/9B9

27 Jan 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.